Status:
COMPLETED
Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients
Lead Sponsor:
Seoul National University Bundang Hospital
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
20-80 years
Phase:
PHASE4
Brief Summary
Triple combination of metformin, DPP4 inhibitor and Thiazolidinedione would be a good option in the treatment of drug-naïve Korean type 2 diabetic patients.
Detailed Description
Thiazolidionedione, a PPARgamman agonist, is an strong insulin sensitizer. It has shown that durable glucose lowering effect and beta cell preservation. It is an important treatment option in patients...
Eligibility Criteria
Inclusion
- HbA1c 9-12%
- No treatment with insulin or oral agents for recent 6 months
- 20 ≤ Age \< 80 years
Exclusion
- Contraindication to sitagliptin or metformin or thiazolidinedione
- Pregnant or breast feeding women
- Type 1 diabetes, gestational diabetes, or secondary forms of diabetes
- Not appropriate for oral antidiabetic agent
- Medication which affect glycemic control
- Disease which affect efficacy and safety of drugs
- Any major illness (Liver disease, Renal failure, Heart disease, Cancer, etc)
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02188186
Start Date
July 1 2014
End Date
September 1 2018
Last Update
March 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 463-707